Chemistry:XL-413
From HandWiki
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| ChemSpider | |
| ChEBI | |
| Chemical and physical data | |
| Formula | C14H12ClN3O2 |
| Molar mass | 289.71 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
XL-413 is a drug which acts as a selective inhibitor of the enzyme cell division cycle 7-related protein kinase (CDC7). It is being researched for the treatment of some forms of cancer, and also has applications in genetic engineering.[1][2][3][4]
References
- ↑ "Discovery of XL413, a potent and selective CDC7 inhibitor". Bioorganic & Medicinal Chemistry Letters 22 (11): 3727–31. June 2012. doi:10.1016/j.bmcl.2012.04.024. PMID 22560567.
- ↑ "The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds". PLOS ONE 9 (11): e113300. 2014. doi:10.1371/journal.pone.0113300. PMID 25412417. Bibcode: 2014PLoSO...9k3300S.
- ↑ "Cell division cycle 7 is a potential therapeutic target in oral squamous cell carcinoma and is regulated by E2F1". Journal of Molecular Medicine 96 (6): 513–525. June 2018. doi:10.1007/s00109-018-1636-7. PMID 29713760.
- ↑ "Timed inhibition of CDC7 increases CRISPR-Cas9 mediated templated repair". Nature Communications 11 (1): 2109. April 2020. doi:10.1038/s41467-020-15845-1. PMID 32355159. Bibcode: 2020NatCo..11.2109W.
 |  |
